Status:
UNKNOWN
Caffeine Efficacy in ADCY5-related Dyskinesia
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
ADCY5-related Dyskinesia
Eligibility:
All Genders
Brief Summary
Heterozygous mutations in ADCY5 induce hyperactivity of striatal adenylate cyclase type 5 (AC5), manifesting as early-onset hyperkinetic movement disorders. Numerous treatments have been tried without...
Detailed Description
Heterozygous mutations in ADCY5 induce hyperactivity of striatal adenylate cyclase type 5 (AC5) manifesting as early-onset hyperkinetic movement disorders. The phenotype combines chorea, dystonia and/...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Proven genetic diagnosis of ADCY5-related dyskinesia
- Adults or children without age limits
- Past or present caffeine intake
- Non-opposition by the patient (adults) or the legal representatives (minors) in France, and patient information according to each country's legislation in other countries.
- 2. Exclusion criteria None.
Exclusion
Key Trial Info
Start Date :
July 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 15 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04469283
Start Date
July 15 2020
End Date
July 15 2021
Last Update
July 14 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.